Investors of Aardvark Therapeutics Face Securities Fraud Class Action Lawsuit

A recent announcement from the national shareholder rights firm Hagens Berman Sobol Shapiro LLP has informed investors regarding a securities class action lawsuit related to Aardvark Therapeutics, Inc. (NASDAQ: AARD). The legal action stems from alleged fraudulent misrepresentation and omissions pertaining to the company's operations and the safety of its products.

Background on Aardvark Therapeutics

Aardvark Therapeutics is a clinical-stage biopharmaceutical company that concentrates on developing therapies targeting bitter taste receptors, specifically for conditions like hyperphagia in Prader-Willi Syndrome (PWS). The company’s product, ARD-101, was poised to provide significant clinical advancements in the treatment process. However, events unfolding from the end of February 2026 raised critical concerns over the company’s transparency and operational integrity.

Details of the Allegations

The lawsuit claims that Aardvark Therapeutics made materially false statements regarding the safety and efficacy of ARD-101. It specifies that prospective investors were misled about the safety of ARD-101, especially concerning unexpected cardiac observations noted during clinical testing. The suit points out that the company failed to disclose serious risks associated with ARD-101’s administration at levels deemed excessive during trials, leading to a grossly inflated perception of Aardvark’s clinical and regulatory success.

On February 27, 2026, Aardvark announced a voluntary halt to the Phase 3 HERO trial, citing these reversible cardiac observations. This announcement triggered a drastic 56% decrease in the company’s stock price, signaling investors’ panic and loss of confidence in the company's future. Subsequently, the FDA imposed a complete clinical hold on the firm’s investigational new drug application for ARD-101 on May 14, 2026. This action prompted another significant decline of 32.1% in Aardvark's stock price, reinforcing the severity of the situation.

Implications for Investors

Investors who acquired Aardvark’s common stock around the time of its initial public offering (IPO) on February 13, 2025, or those who purchased shares between that date and May 14, 2026, are advised to take prompt action. The deadline to motion for lead plaintiff status in this case is set for October 13, 2026. Shareholders affected by the fraudulent activities are encouraged to reach out to Hagens Berman for guidance concerning their potential legal rights and recovery options.

Investigative Efforts by Hagens Berman

Reed Kathrein, the partner leading the investigation into the allegations, emphasized the firm’s commitment to thoroughly examining claims that Aardvark misled its investors. The situation highlights the importance of corporate transparency and accountability within the biopharmaceutical sector, especially given the high stakes involved in drug development and investor trust.

Conclusion and Next Steps for Aardvark Investors

Investors holding Aardvark securities have to act swiftly. If you fit the criteria of being a member of the class that suffered losses, the upcoming deadlines stress the urgency for legal action. Parties with insider information about Aardvark Therapeutics should also consider the potential implications of their knowledge, particularly in light of the SEC’s Whistleblower program that offers financial incentives for accurate reporting.

For further details or to begin the recovery process, affected investors should reach out to Hagens Berman, a respected law firm known for its efforts in holding corporations accountable for their actions and ensuring investor rights are safeguarded.